GPR50 and hepatocellular carcinoma: Thus, our findings revealed the molecular basis underlying the GPR50 and ADAM17 complex-mediated, ligand-independent modulation of the Notch signaling pathway, which can be exploited in Notch-based HCC therapeutic strategies.